Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates

Critical Reviews in Oncology/Hematology

Volumn 82, Issue 2, 2012, Pages 233-248

  Aft, Rebecca ^a   Perez, Jose Ricardo ^b   Raje, Noopur ^c   Hirsh, Vera ^d   Saad, Fred ^e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Disseminated tumor cells; Multiple myeloma; Zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; DOXORUBICIN; OSTEOCLAST DIFFERENTIATION FACTOR; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIRESORPTIVE ACTIVITY; APOPTOSIS; BONE MARROW; BONE METASTASIS; BONE MICROENVIRONMENT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CIRCULATING TUMOR CELL; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG DOSE SEQUENCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MESENCHYMAL STEM CELL; METASTASIS; METASTASIS INHIBITION; MICROENVIRONMENT; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOMIMETISM; OSTEOPOROSIS; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; PROSTATE CANCER; RECURRENCE RISK; REVIEW; SOLID TUMOR; STEM CELL NICHE; TUMOR CELL; TUMOR GROWTH; TUMOR SEEDING; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; DIPHOSPHONATES; DISEASE PROGRESSION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 84859419686     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.05.009     Document Type: Review

References (134)

1. Garcia M., Jemal A., Ward E.M., et al. Global cancer facts & figures, 2007 2007, American Cancer Society, Atlanta.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. American Cancer Society Cancer facts & figures, 2010 2010, American Cancer Society, Atlanta.
4. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3:453-458.
5. Coleman R.E. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?. Eur J Cancer 2009, 45:1909-1915.
6. Musolino A., Ciccolallo L., Panebianco M., et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 2011, 117:1837-1846.
7. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133:571-573.
8. Eidtmann H., de Boer R., Bundred N., et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 2010, 21:2188-2194.
9. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
10. Morgan G.J., Davies F.E., Gregory W.M., et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376:1989-1999.
11. Timar J., Csuka O., Orosz Z., Jeney A., Kopper L. Molecular pathology of tumor metastasis. I. Predictive pathology. Pathol Oncol Res 2001, 7:217-230.
12. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
13. Eyles J., Puaux A.L., Wang X., et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010, 120:2030-2039.
14. Kim M.Y., Oskarsson T., Acharyya S., et al. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
15. Coghlin C., Murray G.I. Current and emerging concepts in tumour metastasis. J Pathol 2010, 222:1-15.
16. Bellahcene A., Bachelier R., Detry C., Lidereau R., Clezardin P., Castronovo V. Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 2007, 101:135-148.
17. Rucci N., Teti A. Osteomimicry: how tumor cells try to deceive the bone. Front Biosci (Schol Ed) 2010, 2:907-915.
18. Zayzafoon M., Abdulkadir S.A., McDonald J.M. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem 2004, 279:3662-3670.
19. Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol 2004, 2:205-213. [discussion 13-4, 16-7, 19-20].
20. Padalecki SS. Prostate cancer metastases to bone: role of high bone turnover induced by androgen deprivation. Annual Report ADA407345. Fort Belvoir, VA: Defense Technical Information Center; 2002. p. 1-21. [accessed 8.11.2010]. http://www.dtic.mil/cgi-bin/GetTRDoc%3FAD=ADA407345%26Location=U2%26doc=GetTRDoc.pdf.
21. Terpos E., Dimopoulos M.A. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005, 16:1223-1231.
22. Meads M.B., Hazlehurst L.A., Dalton W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526.
23. Shiozawa Y., Havens A.M., Pienta K.J., Taichman R.S. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008, 22:941-950.
24. Corso A., Ferretti E., Lazzarino M. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Hematology 2005, 10:215-224.
25. Corso A., Ferretti E., Lunghi M., et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 2005, 104:118-125.
26. Shaked Y., Voest E.E. Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil?. Biochim Biophys Acta 2009, 1796:1-4.
27. Li Calzi S., Neu M.B., Shaw L.C., Kielczewski J.L., Moldovan N.I., Grant M.B. EPCs and pathological angiogenesis: when good cells go bad. Microvasc Res 2010, 79:207-216.
28. Kimura T., Kuwata T., Ashimine S., et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res 2010, 16:121-129.
29. Araki K., Sangai T., Miyamoto S., et al. Inhibition of bone-derived insulin-like growth factors by a ligand-specific antibody suppresses the growth of human multiple myeloma in the human adult bone explanted in NOD/SCID mouse. Int J Cancer 2006, 118:2602-2608.
30. Normanno N., Gallo M., Lamura L., De Luca A. Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment. J Clin Oncol 2010, 28(Suppl.). [abstract 10602].
31. Coscia M., Quaglino E., Iezzi M., et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010, 14:2803-2815.
32. Welsh T.J., Green R.H., Richardson D., Waller D.A., O'Byrne K.J., Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005, 23:8959-8967.
33. Allgayer H., Aguirre-Ghiso J.A. The urokinase receptor (u-PAR)-a link between tumor cell dormancy and minimal residual disease in bone marrow?. APMIS 2008, 116:602-614.
34. Muller V., Stahmann N., Riethdorf S., et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005, 11:3678-3685.
35. Suzuki M., Mose E.S., Montel V., Tarin D. Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am J Pathol 2006, 169:673-681.
36. van der Pluijm G. Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 2011, 48:37-43.
37. Reuben J.M., Lee B.N., Gao H., et al. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+)CD24(lo) cancer stem cell phenotype. Eur J Cancer 2011, February 18 [Epub ahead of print]. 10.1016/j.ejca.2011.01.011.
38. Watson M.A., Ylagan L.R., Trinkaus K.M., et al. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res 2007, 13:5001-5009.
39. Liu S., Ginestier C., Ou S.J., et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011, 71:614-624.
40. Braun S., Vogl F.D., Naume B., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802.
41. Schindlbeck C., Kampik T., Janni W., et al. Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas. Breast Cancer Res 2005, 7:R1174-R1185.
42. Janni W., Wiedswang G., Fehm T., et al. Persistence of disseminated tumor cells (DTC) in bone marrow (BM) during follow-up predicts increased risk of relapse-up-date of the pooled European data. Breast Cancer Res Treat 2006, 100(Suppl. 1):S11. [abstract 18].
43. Berg A., Berner A., Lilleby W., et al. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer 2007, 120:1603-1609.
44. Brunsvig P.F., Flatmark K., Aamdal S., et al. Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients. Lung Cancer 2008, 61:170-176.
45. Garcia J.A., Rosenberg J.E., Weinberg V., et al. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int 2007, 99:519-524.
46. Kollermann J., Weikert S., Schostak M., et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 2008, 26:4928-4933.
47. Morgan T.M., Lange P.H., Porter M.P., et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 2009, 15:677-683.
48. Passlick B., Kubuschok B., Izbicki J.R., Thetter O., Pantel K. Isolated tumor cells in bone marrow predicts reduced survival in lymph node-negative non-small-cell lung cancer. Pneumologie 2000, 54:355-360.
49. Sugio K., Kase S., Sakada T., et al. Micrometastasis in the bone marrow of patients with lung cancer associated with a reduced expression of E-cadherin and beta-catenin: risk assessment by immunohistochemistry. Surgery 2002, 131:S226-S231.
50. Bidard F.C., Kirova Y.M., Vincent-Salomon A., et al. Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. Ann Oncol 2009, 20:1836-1841.
51. Bidard F.C., Vincent-Salomon A., Sigal-Zafrani B., et al. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 2008, 19:496-500.
52. Cristofanilli M., Hayes D.F., Budd G.T., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23:1420-1430.
53. Green J.R. Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol 2001, 28:4-10.
54. Kavanagh K.L., Guo K., Dunford J.E., et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 2006, 103:7829-7834.
55. Rondeau J.M., Bitsch F., Bourgier E., et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 2006, 1:267-273.
56. Russell R.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007, 119(Suppl. 2):S150-S162.
57. Frith J.C., Monkkonen J., Blackburn G.M., Russell R.G., Rogers M.J. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997, 12:1358-1367.
58. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589.
59. Monkkonen H., Auriola S., Lehenkari P., et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 2006, 147:437-445.
60. Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther 2007, 4:92-100.
61. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925-4935.
62. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
63. Terpos E., Berenson J., Cook R.J., Lipton A., Coleman R.E. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010, 24:1043-1049.
64. Lipton A., Cook R., Saad F., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
65. Lipton A., Chapman J.W., Demers L., et al. Elevated bone resorption predicts shorter recurrence-free survival for bone metastasis in breast cancer. Presented at Primary Therapy of Early Breast Cancer 11th International Conference 2009, [abstract 244].
66. Hirsh V., Major P.P., Lipton A., et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008, 3:228-236.
67. Diel I.J., Jaschke A., Solomayer E.F., et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008, 19:2007-2011.
68. Powles T., Paterson A., McCloskey E., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006, 8:R13.
69. Saarto T., Vehmanen L., Virkkunen P., Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43:650-656.
70. Dearnaley D.P., Mason M.D., Parmar M.K., Sanders K., Sydes M.R. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009, 10:872-876.
71. Brufsky A.M., Bosserman L.D., Caradonna R.R., et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85.
72. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840-849.
73. Gnant M., Mlineritsch B., Stoeger H., et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. J Clin Oncol 2010, 28(Suppl.):75s. [abstract 533].
74. Coleman R.E., Thorpe H.C., Cameron D., et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Presented at 33rd Annual San Antonio Breast Cancer Symposium 2010, [abstract S4-5].
75. Chlebowski R.T., Chen Z., Cauley J.A., et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010, 28:3582-3590.
76. Newcomb P.A., Trentham-Dietz A., Hampton J.M. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010, 102:799-802.
77. Rennert G., Pinchev M., Rennert H.S. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010, 28:3577-3581.
78. Santini D., Vincenzi B., Galluzzo S., et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007, 13:4482-4486.
79. Vincenzi B., Santini D., Dicuonzo G., et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005, 25:144-151.
80. Dieli F., Vermijlen D., Fulfaro F., et al. Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007, 67:7450-7457.
81. Kunzmann V., Bauer E., Feurle J., Weissinger F., Tony H.P., Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384-392.
82. Roelofs A.J., Thompson K., Gordon S., Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006, 12:6222s-6230s.
83. Benzaid I., Mönkkönen H., Stresing V., et al. Zoledronate-induced IPP/ApppI (phosphoantigen) accumulation in human breast cancer cells correlates with Vγ9Vδ2 T cell-mediated cancer cell death in vitro and in vivo. Bone 2010, 46(Suppl. 1):S43. [abstract 93].
84. Yamada J., Tsuno N.H., Kitayama J., et al. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res 2009, 151:115-120.
85. Fiore F., Castella B., Nuschak B., et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 2007, 110:921-927.
86. Todaro M., D'Asaro M., Caccamo N., et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009, 182:7287-7296.
87. Pan B., Farrugia A.N., To L.B., et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 2004, 19:147-154.
88. Rack B., Juckstock J., Genss E.M., et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010, 30:1807-1813.
89. Aft R., Naughton M., Trinkaus K., et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421-428.
90. Lin A.Y., Park J.W., Scott J., et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol 2008, 26(Suppl.):20s. [abstract 559].
91. Solomayer E., Gebauer G., Hirnle P., et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res 2009, 69(Suppl. 2):170s-171s. [abstract 2048].
92. Corey E., Brown L.G., Quinn J.E., et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003, 9:295-306.
93. Daubine F., Le Gall C., Gasser J., Green J., Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007, 99:322-330.
94. Kimura S., Kuroda J., Segawa H., et al. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 2004, 79:37-43.
95. Ottewell P.D., Deux B., Monkkonen H., et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 2008, 14:4658-4666.
96. Ottewell P.D., Lefley D.V., Cross S.S., Evans C.A., Coleman R.E., Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2010, 126:522-532.
97. Ottewell P.D., Monkkonen H., Jones M., Lefley D.V., Coleman R.E., Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008, 100:1167-1178.
98. Ottewell P.D., Woodward J.K., Lefley D.V., Evans C.A., Coleman R.E., Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009, 8:2821-2832.
99. Winter M.C., Holen I., Coleman R.E. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008, 34:453-475.
100. Yuasa T., Kimura S., Ashihara E., Habuchi T., Maekawa T. Zoledronic acid-a multiplicity of anti-cancer action. Curr Med Chem 2007, 14:2126-2135.
101. McAllister S.S., Gifford A.M., Greiner A.L., et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008, 133:994-1005.
102. McAllister S.S., Weinberg R.A. Tumor-host interactions: a far-reaching relationship. J Clin Oncol 2010, 28:4022-4028.
103. Melani C., Sangaletti S., Barazzetta F.M., Werb Z., Colombo M.P. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007, 67:11438-11446.
104. Roelofs A.J., Coxon F.P., Ebetino F.H., et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010, 25:606-616.
105. Clezardin P., Ebetino F.H., Fournier P.G. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005, 65:4971-4974.
106. Coxon J.P., Oades G.M., Kirby R.S., Colston K.W. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004, 94:164-170.
107. Croucher P.I., De Hendrik R., Perry M.J., et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003, 18:482-492.
108. Denoyelle C., Hong L., Vannier J.P., Soria J., Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 2003, 88:1631-1640.
109. Jagdev S.P., Coleman R.E., Shipman C.M., Rostami H.A., Croucher P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001, 84:1126-1134.
110. Kuroda J., Kimura S., Segawa H., et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 2003, 102:2229-2235.
111. Neville-Webbe H.L., Coleman R.E., Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer 2010, 102:1010-1017.
112. Neville-Webbe H.L., Rostami-Hodjegan A., Evans C.A., Coleman R.E., Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005, 113:364-371.
113. Michailidou M., Brown H.K., Lefley D.V., et al. Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?. J Vasc Res 2010, 47:481-493.
114. Li Y.Y., Chang J.W., Chou W.C., et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 2008, 59:180-191.
115. Lu S., Zhang J., Zhou Z., et al. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncol Rep 2008, 20:581-587.
116. Lawson M.A., Ashcroft J., Croucher P.I. Bisphosphonate therapy in the treatment of multiple myeloma. Curr Pharm Des 2010, 16:3028-3036.
117. Guenther A., Gordon S., Tiemann M., et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010, 126:239-246.
118. Guise T.A. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 2008, 34(Suppl. 1):S19-S24.
119. Coleman R.E., Winter M.C., Cameron D., et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102:1099-1105.
120. Aft R., Naughton M., Trinkaus K., Weilbacher K. Effect of zoledronic acid on disease-free survival and overall survival in women with clinical stage II/III undergoing neoadjuvant chemotherapy for breast cancer. Cancer Res 2010, 70(Suppl. 1):458s-459s. [abstract P6-14-04].
121. Lipton A. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?. Breast Cancer Res Treat 2010, 122:627-636.
122. Xgeva™ [package insert] 2010, Amgen, Inc., Thousand Oaks, CA.
123. Canon J., Bryant R., Roudier M., et al. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone 2010, 46:1613-1619.
124. Odero-Marah V.A., Wang R., Chu G., et al. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res 2008, 18:858-870.
125. Wilson T.J., Nannuru K.C., Futakuchi M., Sadanandam A., Singh R.K. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res 2008, 68:5803-5811.
126. Henry D.H., Costa L., Goldwasser F., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
127. Mystakidou K., Katsouda E., Parpa E., Kelekis A., Galanos A., Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005, 22:195-201.
128. Pandya K.J., Gajra A., Warsi G.M., Argonza-Aviles E., Ericson S.G., Wozniak A.J. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer 2010, 67:330-338.
129. Zaghloul M.S., Boutrus R., El-Hossieny H., Kader Y.A., El-Attar I., Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010, 15:382-389.
130. Zarogoulidis K., Boutsikou E., Zarogoulidis P., et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009, 125:1705-1709.
131. Calderone R.G., Nimako K., Leary A.N., Popat S., Kipps E., O'Brien M.N. Use of zoledronic acid in lung cancer. J Thorac Oncol 2010, 5(Suppl. 1):S99-S100. [abstract 253P].
132. Karamanos N., Zarogoulidis K., Boutsikou E., Zarogoulidis P., Kontakiotis T. Prolonged survival and time to disease progression with zoledronic acid in patients with bone metastases from non-small cell lung cancer. J Clin Oncol 2010, 28(Suppl.). [abstract e18077].
133. Body J.J., Coleman R., Clezardin P., Ripamonti C., Rizzoli R., Aapro M. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007, 43:852-858.
134. Santini D., Fratto M.E., Galluzzo S., Vincenzi B., Tonini G. Are bisphosphonates the suitable anticancer drugs for the elderly?. Crit Rev Oncol Hematol 2009, 69:83-94.